Practice 04 · Commercial strategy

A credible route from product to patients and customers.

We define what the product must prove, who adopts and pays first, and how it reaches the market, so the commercial story holds up with investors and partners.

Book a 20-minute call What we deliver

Line drawing of a hatchetfish on a square grid, and the same outline on a sheared grid, becoming a related species.

Bring us in when

The science is strong, but the path to customers is vague
You are choosing between indications or markets
You are preparing for first customers, pilots or payers

What we deliver

Target product profile

What the product must prove to be adopted, paid for and partnered.

Beachhead and indications

The first patients or customers, and why they come first.

Competitive positioning

An honest landscape, and the case for why you win.

Pricing and market access

Pricing logic, reimbursement and payer considerations by market.

Go-to-market

Buyer, channel and sales motion for devices, diagnostics and tools.

Global expansion

Market prioritization and launch planning across regions.

Typical outputsTarget product profileCompetitive landscapePricing analysisGo-to-market plan

Ways to start

Fixed scope, clear deliverables.

Fees are fixed and agreed before we start. We will recommend the right starting point on the intro call.

Business Model and Valuation Sprint

2 to 3 weeks

A bottom-up market model, revenue logic, NPV or rNPV, and an operating plan tied to the raise.

Best for: A story without numbers behind it

Strategic Advisory

90 days or more, limited availability

Ongoing work with a small number of companies at a time: strategy sessions, review of materials and models, and meeting preparation.

Best for: Senior counsel through a raise or a deal

Related work

Pre-seed · AI software for biopharma

One source of truth

Strong founder-market fit and two signed pilots, but the deck, one-pager and outreach note used different numbers, and the round needed a check against the stage.

What changed: Materials ready for vertical AI, techbio and enterprise software investors who understand regulated buyers.

Read the case

The experience behind this practice

Corporate strategy for $10B+ vaccines and hospital product portfolios at Pfizer, and new market expansion into LatAm, MENA, Turkey and Israel at BeiGene.
Market access initiatives at the Clinton Health Access Initiative, in partnership with WHO, UNAIDS, UNICEF, USAID and the Global Fund.

From Bio Founder GPS

Sep 14, 2026

Before we speak.

Other practices

Not for investors. They will ask who pays and why at every stage, and the answer shapes your development plan and your raise.

Book a 20-minute call

Talk through your situation in 20 minutes.

You'll speak with Vadim Shepel

Founder and Principal, Bench2Bio

01
Where you are
Your stage, your science and what is coming next: a raise, a partner conversation or a decision.
02
What investors or partners will test
An honest read on the gaps that will matter most, even if we never work together.
03
Whether and how we can help
A recommended starting point, or a referral if someone else is a better fit.

Prefer email? vadim@bench2bio.com

Choose a timeOpen in Calendly